Apyx Medical (FRA:BOV) Tariff Resilience Score: 5/10 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BOV Apyx Medical Corp FRA:BOV
72 GF Score
Price €2.56
GF Value €1.85
! 2 Warning Signs
View Full Analysis

What is Apyx Medical Tariff Resilience Score?

Apyx Medical FRA:BOV 72 Tariff Resilience Score is 5 as of Aug. 18, 2026. GuruFocus rates FRA:BOV with a GF Score™ of 72/100 and a GF Value™ of €1.85. The stock has 2 warning signs investors should review. Among 827 Medical Devices & Instruments companies, Apyx Medical ranks better than 79.2% on this metric.

Apyx Medical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Apyx Medical has Apyx Medical Corp faces moderate tariff exposure due to its reliance on international manufacturing and sales. Medical devices can be subject to tariffs, but industry-specific exemptions and alternative suppliers provide some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Apyx Medical might have Average Resilient.

Apyx Medical  (FRA:BOV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Apyx Medical Tariff Resilience Score Related Terms

FRA:BOV vs INGN, QSI, QTRX: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Apyx Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apyx Medical Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Tariff Resilience Score falls into.


FRA:BOV
72GF Score
Apyx Medical Corp FRA:BOV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Apyx Medical (FRA:BOV) has a Tariff Resilience Score of 5 as of Aug. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Apyx Medical ranks #172 out of 827 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Apyx Medical's Tariff Resilience Score too high?
Apyx Medical's current Tariff Resilience Score is 5. Based on the distribution chart, Apyx Medical ranks #172 out of 827 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Tariff Resilience Score compare to INGN and QSI?
According to the Medical Devices & Instruments industry distribution chart, Apyx Medical ranks #172 out of 827 companies for Tariff Resilience Score. This places Apyx Medical in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Apyx Medical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €1.85, compared to a current price of €2.56 — trading 38.4% above its estimated fair value. The current Tariff Resilience Score is 5. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current Tariff Resilience Score is 5 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apyx Medical (FRA:BOV) Overvalued in 2026?

Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued. The current stock price of €2.56 is trading 38.4% above its estimated GF Value™ of €1.85.

Key valuation signals for FRA:BOV:

  • Tariff Resilience Score: 5
  • GF Value™: €1.85 vs. price of €2.56 (38.4% above fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apyx Medical Business Description

Other Exchanges APYX:USA
Address 5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score

Get the complete analysis for FRA:BOV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price
€1.85
GF Value